Proxy fight at Echo Therapeutics

|About: Echo Therapeutics (ECTE)|By:, SA News Editor

A proxy fight over the election of a director looms at Echo Therapeutics' (ECTE +2.4%) June 19 shareholders meeting. The company favors current director and interim CEO Robert F. Doman while institutional shareholder Platinum Management favors Shepard M. Goldberg. As is usually the case, the core of the dispute pertains to the strategic direction of the company.